Pci Pharma Services
PCI Pharma Services, headquartered in the United States, is a leading provider in the pharmaceutical and biotechnology sectors, specialising in drug development and manufacturing solutions. Founded in 1920, the company has established a strong presence across North America and Europe, offering a comprehensive range of services that include drug formulation, clinical trial services, and commercial manufacturing. With a commitment to innovation, PCI Pharma Services stands out for its integrated approach, combining advanced technology with deep industry expertise. The company has achieved significant milestones, including numerous successful product launches and partnerships with major pharmaceutical firms. Renowned for its quality and reliability, PCI Pharma Services continues to solidify its market position as a trusted partner in the life sciences industry, dedicated to enhancing patient outcomes through effective drug delivery solutions.
DitchCarbon Score
How does Pci Pharma Services's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pci Pharma Services's score of 12 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pci Pharma Services's reported carbon emissions
In 2023, PCI Pharma Services reported total greenhouse gas emissions of approximately 65,000,000 kg CO2e, comprising 27,000,000 kg CO2e from Scope 1 and 38,000,000 kg CO2e from Scope 2 emissions. This marked an increase from 2022, where total emissions were about 38,000,000 kg CO2e, with 12,000,000 kg CO2e from Scope 1 and 26,000,000 kg CO2e from Scope 2. In 2021, the company had total emissions of around 33,000,000 kg CO2e, with 7,000,000 kg CO2e from Scope 1 and 26,000,000 kg CO2e from Scope 2. PCI Pharma Services has committed to achieving net-zero emissions across all scopes by 2050, with a long-term target established in 2023. The company is actively working towards this goal, aligning its strategies with the Science Based Targets initiative (SBTi). The commitment reflects a growing trend in the pharmaceutical industry to address climate change and reduce carbon footprints. Overall, PCI Pharma Services is taking significant steps to manage its carbon emissions while striving for sustainability in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 7,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 26,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pci Pharma Services is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
